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to-moderate bleeds in a hemophilia patient with inhibitors is very
high. When considering the impact of rebleeding over multiple
lines of treatment, the rFVIIa-only regimen, versus APCC-con-
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OBJECTIVES: Patients with transfusion-dependent thalassemia
require chelation to prevent complications from transfusional
iron overload. Deferoxamine (DFO) is an effective iron chelator,
but must be administered as a subcutaneous or intravenous infu-
sion over 8–12 hours 5–7 times per week leading to poor com-
pliance and/or quality of life in many patients. METHODS: We
developed a Markov model using data from published studies
and other sources to estimate the lifetime incidence and medical
care costs of complications of iron overload that are attributable
to inadequate compliance with DFO therapy in patients with
transfusion-dependent thalassemia. Complications considered
included cardiac disease, diabetes, hypogonadism, hypoparathy-
roidism, hypothyroidism, and death due to cardiac disease.
Current compliance with DFO therapy as well as costs of com-
plications were obtained from an analysis of health insurance
claims data. Adequate compliance was deﬁned as 260 infusions
per year (i.e., ﬁve per week). Costs were discounted at 3% annu-
ally. RESULTS: Current mean DFO use was estimated to be 169
infusions annually. At this level of compliance, 95% of patients
are projected to experience cardiac disease during their lifetime,
diabetes 46%, hypogonadism 77%, hypoparathyroidism 32%,
and hypothyroidism 26%. Cardiac-disease-free life expectancy is
projected to be 23 years; overall life expectancy, 28 years. The
expected lifetime cost of complications of iron overload is
$54,151 per patient. If mean compliance were to increase to 260
infusions per year, the lifetime risk of cardiac disease would
decline to 60%, diabetes to 9%, hypogonadism to 47%, and
hypothyroidism to 14%. Cardiac-disease-free and overall life
expectancy would increase by 22 and 19 years respectively. The
discounted expected lifetime costs of complications of iron over-
load would decline by $30,222. CONCLUSIONS: Inadequate
compliance with DFO therapy in patients with transfusion-
dependent thalassemia results in substantial morbidity and 
mortality, as well as increased medical care costs associated with
complications of iron overload.
PHM5
PILOT STUDY TO ESTABLISH PREFERENCES TOWARDS
COAGULATION FACTOR CONCENTRATES USED TO TREAT
HAEMOPHILIC PATIENTS WITH INHIBITORS
Scalone L1, Gringeri A2, Borghetti F1, Ravera S1, Casati A1, Mantovani
LG1
1Center of Pharmacoeconomics, University of Milan, Milan, Italy, Italy,
2A. Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS
Found. Policlinico, Mangiagalli, Regina Elena Hosp. and Univ. of Milan,
Milan, Italy, Italy
OBJECTIVES: Haemophilia is a very expensive disease. This sit-
uation becomes extreme when patients develop inhibitors that
compromise the effectiveness of treatment, with potential
increase of morbidity and mortality. Treatment of haemophilia
is the result of interactions between patients, physicians, phar-
macists and budget holders, each carrying their own set of 
preferences. A pilot study was conducted to identify which char-
acteristic of coagulation products are considered more important
to treat patients with inhibitors: these characteristics will be
included with a price proxy characteristic in a Discrete Choice
Experiment, with the objective to elicit preferences and willing-
ness to pay towards treatments of patients with inhibitors.
METHODS: Eight characteristics were identiﬁed during focus
groups with patients and clinicians and rated from 0 (not impor-
tant) to 10 (very important) by 35 people (adult patients, care-
givers, physicians, pharmacists). RESULTS: the following
median (mean) scores were found: “viral safety”: 10 (8.9); “time
to stop bleeding”: 9.5 (9.0); “risk of anamnestic response”: 9.0
(8.5); “possibility of undergoing major surgery”: 9.0 (8.8);
“regular use in prophylaxis”: 9.0 (8.4); “time to pain recovery”:
9.0 (8.3); “number of injections to stop bleeding”: 8.0 (7.9);
“time to prepare and give/have the injection”: 7.0 (6.6). All
groups of respondents considered as more important “viral
safety”, “possibility of undergoing major surgery”, “risk of
anamnestic response”, “time to stop bleeding”, while “time to
prepare and give/have the injection” was considered the least
important. Different preferences were attributed to “time to pain
recovery”, considered more important by patients; “regular use
in prophylaxis”, considered more important by caregivers.
CONCLUSIONS: Viral safety and effectiveness are considered
as the most important characteristics in the treatment of
haemophilic patients with inhibitors. Different levels of prefer-
ences are present between patients, or their caregivers, and physi-
cians. Understanding these differences is important to guide
optimal therapeutic strategies in patients with inhibitors.
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OBJECTIVE: To determine and quantify the unique character-
istics of clinical trial participants in comparison to the general
patient population. METHODS: Data were obtained from the
U.S. National Health and Wellness Survey, an annual, nationally
representative, Internet-based study of the health care attitudes
and behaviors of non-institutionalized adults age 18+. The
sample for analysis included 18,419 respondents who reported
a diagnosis of hypertension, high cholesterol, or diabetes.
Respondents reported ever participating in a clinical drug trial.
They also provided information on demographics, healthcare
attitudes, health habits, quality of life measured by the SF-8, and
healthcare resource use in the past six months. RESULTS:
Among respondents diagnosed with hypertension, high choles-
terol, or diabetes, 7% (n = 1333) have participated in a clinical
drug trial. Clinical trial participants signiﬁcantly differ from the
general patient population in many key characteristics. Clinical
trial participants are signiﬁcantly older (mean age 60.5 versus
55.1, p < 0.001) and more educated (college graduates 43%
versus 36%, p < 0.001). They experience worse physical well-
being (sf-8 physical component summary score 43.1 versus 45.3,
p < 0.001), though are more likely to maintain a healthy diet
(50% versus 46%, p = 0.002) and less likely to smoke (18%
versus 23%, p < 0.001). Clinical trial participants are more
